2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

Author(s):
Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; Backer, G.G. de; Delgado, V.; Ference, B.A.; Graham, I.M.; Halliday, A.; Landmesser, U.; Mihaylova, B.; Pedersen, T.R.; Riccardi, G.; Richter, D.J.; Sabatine, M.S.; Taskinen, M.R.; Tokgozoglu, L.; Wiklund, O.; Mueller, C.; Drexel, H.; Aboyans, V.; Corsini, A.; Doehner, W.; Farnier, M.; Gigante, B.; Kayikcioglu, M.; Krstacic, G.; Lambrinou, E.; Lewis, B.S.; Masip, J.; Moulin, P.; Petersen, S.; Petronio, A.S.; Piepoli, M.F.; Pinto, X.; Raber, L.; Ray, K.K.; Reiner, Z.; Riesen, W.F.; Roffi, M.; Schmid, J.P.; Shlyakhto, E.; Simpson, I.A.; Stroes, E.; Sudano, I.; Tselepis, A.D.; Viigimaa, M.; Vindis, C.; Vonbank, A.; Vrablik, M.; Vrsalovic, M.; Gomez, J.L.Z.; Collet, J.P.; European Soc Cardiology; European Atherosclerosis Soc
Published
2020
Publication type
Article / Letter to editor
Guidelinesdyslipidaemiascholesteroltriglycerideslow-density lipoproteinshigh-density lipoproteinsapolipoprotein Blipoprotein(a)lipoprotein remnantstotal cardiovascular risktreatment (lifestyle)treatment (drugs)treatment (adherence)very low-density lipoproteinsfamilial hypercholesterolaemia
Date issued
2020-01-01
Language
English
Publisher
OXFORD UNIV PRESS
Is part of
European Heart Journal (2020), Vol. 41, no. 1, p. 111-188
hdl
1887/3232686
doi
10.1093/eurheartj/ehz455
URL
https://academic.oup.com/eurheartj/article/41/1/111/5556353